PharmaShots | Incisive News in 3 Shots

Subscribe Now

Phase 2

PharmaShots Interview: Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis

PharmaShots Interview: Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia A...

February 28, 2022

BMS Deucravacitinib Fails to Meet its Primary and Secondary Endpoints in P-II LATTICE-UC Study for the Treatment of Moderate to Severe Ulcerative Colitis

BMS Deucravacitinib Fails to Meet its Primary and Secondary Endpoints in P-II LATTICE-UC Study for the Treatment of Moderate to Se...

October 7, 2021

Biogen Reports Mixed Results of Vixotrigine (BIIB074) in P-II CONVEY Study for the Treatment of Small Fiber Neuropathy

Biogen Reports Mixed Results of Vixotrigine (BIIB074) in P-II CONVEY Study for the Treatment of Small Fiber Neuropathy

September 17, 2021

PharmaShots Interview: Medicago's Nathalie Landry Shares Insights on the Phase 2 Results of Plant-Based COVID-19 Vaccine

PharmaShots Interview: Medicago's Nathalie Landry Shares Insights on the Phase 2 Results of Plant-Based COVID-19 Vaccine

June 29, 2021

Kyowa Annouces P-IIa Results of KW-6356 for Parkinson's Disorder at IAPRD

Kyowa Annouces P-IIa Results of KW-6356 for Parkinson's Disorder at IAPRD

August 21, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us